Local Coverage Determination (LCD):
Pathology and Laboratory: Molecular Pathology Procedures for Human Leukocyte Antigen (HLA) Typing (L34943)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

Contractor Name
Cahaba Government Benefit Administrators®, LLC

Contract Number
10302

Contract Type
MAC - Part B

LCD Information

Document Information

LCD ID
L34943

Original ICD-9 LCD ID
L34511

LCD Title
Pathology and Laboratory: Molecular Pathology Procedures for Human Leukocyte Antigen (HLA) Typing

AMA CPT / ADA CDT / AHA NUBC Copyright Statement
CPT only copyright 2002-2015 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright © American Dental Association. All rights reserved. CDT and CDT-2010 are trademarks of the American Dental Association.

UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association ("AHA"), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA.” Health Forum reserves the right to change the copyright notice from time to time upon written notice to Company.

Jurisdiction
Tennessee

Original Effective Date
For services performed on or after 10/01/2015

Revision Effective Date
For services performed on or after 10/01/2015

Revision Ending Date
N/A

Retirement Date
N/A

Notice Period Start Date
N/A

Notice Period End Date
N/A

Printed on 11/11/2015. Page 1 of 9
CMS National Coverage Policy

- Title XVIII of the Social Security Act, Section 1833(e). This section states that no payment shall be made to any provider for any claims that lack the necessary information to process the claim.
- Title XVIII of the Social Security Act, Section 1862(a)(1)(A). This section allows coverage and payment for only those services that are considered to be reasonable and medically necessary, i.e., reasonable and necessary are those tests used in the diagnosis and management of illness or injury or to improve the function of a malformed body part.
- Title XVIII of the Social Security Act, Section 1862(a)(1)(D). Investigational or Experimental.
- Title XVIII of the Social Security Act, Section 1862(a)(7). This section excludes routine physical examinations and services.
- 42 CFR Section 410.32(a) indicates diagnostic tests are payable only when the physician who is treating the beneficiary for a specific medical problem uses the results in such treatment.
- Medicare Benefit Policy Manual (Pub.100-02), Chapter 15, Sections 80.1, 80.1.1, 80.1.2, 80.1.3.
- Medicare Program Integrity Manual (Pub. 100-08), Chapter 13.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Background

Human Leukocyte Antigen (HLA) typing is performed to assess compatibility of recipients and potential donors as a part of solid organ and hematopoietic stem cell/ bone marrow pre-transplant testing. HLA testing is also performed to identify HLA alleles and allele groups (antigen equivalents) associated with specific diseases and individualized responses to drug therapy (e.g., HLA-B*27 and ankylosing spondylitis and HLA-B57:01 and abacavir hypersensitivity), as well as other clinical uses. One or more HLA genes may be tested in specific clinical situations (e.g., HLA A, B, C, -DRB1, and DQB1 for kidney transplantation). Each HLA gene typically has multiple variant alleles or allele groups that can be identified by typing.

HLA antigens are divided into types: Class I (A, B, C) and Class II (DR, DP, DQ). The primary use for HLA testing is to match organ and tissue transplant recipients with compatible donors. Different kinds of transplants necessitate different levels of matching between donor and intended recipient. This may determine which HLA tests are performed and which HLA genes are tested for. HLA typing identifies the unique constellation of HLA antigens for an individual.

HLA typing using newer DNA technologies provides tests that are more robust, accurate and reliable in resolving allele-level differences in HLA genes that cannot be detected by serology. DNA tests can be performed using a variety of source materials (lymphocytes, whole blood, buccal swabs, biopsy samples, frozen tissue) and are less affected by viability and sample age. Several approaches to HLA typing are used, offering a range of typing resolution levels from low (antigen-level) to high (allele-level). Examples include, tests used to identify HLA types that rely on amplification of limited stretches of genomic DNA within the HLA genes. The genetic polymorphisms associated with the different HLA alleles are identified through hybridization with specific amplification primers: sequence-specific primer (SSP) or sequence specific oligonucleotide probes (SSO) or by direct sequencing-based typing (SBT).

PCR-SSO

Reverse SSO hybridization is used to determine HLA-A, -B, -C, -DR, -DQ and -DP locus types at an intermediate level of resolution, somewhat higher than serological testing. Tests of this type are used when low or intermediate resolution typing is required or as a screening test to identify potential donors or individuals who may later require higher resolution testing.

This technology is used for high volume testing and allows for relatively low-cost typing for bone marrow donor drives or other applications involving large sample numbers.

PCR-SSP

PCR-SSP is also used to determine HLA-DP and to determine, at a resolution similar to serological testing, HLA-A, -B, -C, -DR and DQ locus types. PCR-SSP is a very rapid test that can be performed in 3-4 hours from the time a
Transplantation:

A. Standard of care determination of HLA matching for solid organ transplant (donor/recipient). Solid organ transplant registries include both serological HLA testing (e.g. crossmatch) and genomic molecular DNA typing. Family members, or unrelated living donors or cadaveric donors who donate bone marrow or a solid organ are HLA tested pretransplant to determine compatibility with the potential recipients.

B. Standard of care identification of determination of HLA matching for hematopoietic stem cell/bone marrow transplantation. Allele-level typing will provide clinical guidance for the HLA-A,B,C Class I and DRB1, DQB1,DPB1, and DQA1 Class II loci in the average transplant program because it is well established that mismatches at certain HLA loci between donor-recipients are closely linked to the risk of graft versus host disease. Potential marrow donors may enroll with a national registry such as the United States National Marrow Donor Program or the Canadian Blood Services registry.

Disease Association:

A. Standard of care testing to diagnose certain HLA related diseases/conditions when the testing is supported by the clinical literature and is informative for the direct management of a patient bearing a certain allele(s). It is not expected that more than one test would be required in a given beneficiary’s lifetime. Possible covered indications when standard laboratory testing (tissue typing) is not adequate:

i. HLA-B*27 for the diagnosis of certain cases of symptomatic patients with presumed ankylosing spondylitis or related inflammatory disease. HLA-B*27 is covered for ankylosing spondylitis in cases where other methods of diagnosis would not be appropriate or have yielded inconclusive results (National Coverage Determination 190.1).

ii. In the work-up of certain patients with an unclear diagnosis of celiac disease and gluten hypersensitivity usually related to ambiguous standard laboratory results and/or inconsistent biopsy results (e.g., HLA-DQ2 by HLA-DQB1*02 and of DQ8 by HLA-DQB1*0302).

Pharmacogenetics:

A. Standard of care testing to diagnose certain HLA related drug hypersensitivity reactions when the testing is supported by the clinical literature and is informative for the direct management of a patient bearing a certain allele(s) associated to fatal skin drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis). It is not expected that more than one test would be required in a given beneficiary’s lifetime. Possible covered indications:

i. HLA -B*5701 when testing performed prior to the initiation of an abacavir-containing regime in the treatment of HIV Infection.

ii. HLA-B*1502 when genotyping may be useful for risk stratification when the testing is performed prior to the initiation of carbamazepine therapy in the treatment of patients at high risk of having this allele. HLA-B*1502 occurs almost exclusively in patients with ancestry across broad areas of Asia, including South Asian Indians.

Indications

The commercial availability does not ensure that a molecular diagnostic test is indicated for clinical application. Molecular diagnostic testing is a rapidly evolving science in which the significance of detecting specific mutations has yet to be clarified in many circumstances. Analytical and clinical validity as well as clinical utility are the responsibility of the provider, and all testing must meet standards of care.

For the purpose of this LCD, the Molecular Pathology Procedures for HLA typing will be considered medically and reasonable necessary when the following apply:

1. Transplantation:
   A. Standard of care determination of HLA matching for solid organ transplant (donor/recipient). Solid organ transplant registries include both serological HLA testing (e.g. crossmatch) and genomic molecular DNA typing. Family members, or unrelated living donors or cadaveric donors who donate bone marrow or a solid organ are HLA tested pretransplant to determine compatibility with the potential recipients.

   B. Standard of care identification of determination of HLA matching for hematopoietic stem cell/bone marrow transplantation. Allele-level typing will provide clinical guidance for the HLA-A,B,C Class I and DRB1, DQB1,DPB1, and DQA1 Class II loci in the average transplant program because it is well established that mismatches at certain HLA loci between donor-recipients are closely linked to the risk of graft versus host disease. Potential marrow donors may enroll with a national registry such as the United States National Marrow Donor Program or the Canadian Blood Services registry.

2. Disease Association:
   A. Standard of care testing to diagnose certain HLA related diseases/conditions when the testing is supported by the clinical literature and is informative for the direct management of a patient bearing a certain allele(s). It is not expected that more than one test would be required in a given beneficiary’s lifetime. Possible covered indications when standard laboratory testing (tissue typing) is not adequate:

   i. HLA-B*27 for the diagnosis of certain cases of symptomatic patients with presumed ankylosing spondylitis or related inflammatory disease. HLA-B*27 is covered for ankylosing spondylitis in cases where other methods of diagnosis would not be appropriate or have yielded inconclusive results (National Coverage Determination 190.1).

   ii. In the work-up of certain patients with an unclear diagnosis of celiac disease and gluten hypersensitivity usually related to ambiguous standard laboratory results and/or inconsistent biopsy results (e.g., HLA-DQ2 by HLA-DQB1*02 and of DQ8 by HLA-DQB1*0302).

3. Pharmacogenetics:
   A. Standard of care testing to diagnose certain HLA related drug hypersensitivity reactions when the testing is supported by the clinical literature and is informative for the direct management of a patient bearing a certain allele(s) associated to fatal skin drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis). It is not expected that more than one test would be required in a given beneficiary’s lifetime. Possible covered indications:

   i. HLA –B*5701 when testing performed prior to the initiation of an abacavir-containing regime in the treatment of HIV Infection.

   ii. HLA-B*1502 when genotyping may be useful for risk stratification when the testing is performed prior to the initiation of carbamazepine therapy in the treatment of patients at high risk of having this allele. HLA-B*1502 occurs almost exclusively in patients with ancestry across broad areas of Asia, including South Asian Indians.
4. Identification of HLA compatible platelets for transfusion.

**Limitations**

The following will be considered noncovered as applicable due to statutory exclusion, lack of Medicare benefit, not reasonable and necessary, or not separately billable (a component of the service per NCCI regulations).

1. Tests considered screening in the absence of clinical signs and symptoms of disease (e.g., HLA-DQB1*06:02P as a positive/negative predictor for narcolepsy).

2. Tests that do not provide the clinician with actionable data (information that will improve patient outcomes and/or change physician care and treatment of the patient).

3. Tests that confirm a known diagnosis or known information (and no new data for decision making).

4. Tests to determine risk for developing a disease or condition.

5. Tests without diagnosis specific indications.

6. Tests performed to measure the quality of a process.

7. Tests for Quality Control/Quality Assurance (QC/QA), i.e., tests performed to ensure a tissue specimen matches the patient.

8. Tests assessing the risk of allopurinol hypersensitivity reactions (HLA-B*58:01P).

**Coding Information**

**Bill Type Codes:**

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

N/A

**Revenue Codes:**

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

N/A

**CPT/HCPCS Codes**

**Group 1 Paragraph:** N/A

**Group 1 Codes:**

81370  Hla i & ii typing lr
81371  Hla i & ii type verify lr

Printed on 11/11/2015. Page 4 of 9
ICD-10 Codes that Support Medical Necessity

**Group 1 Paragraph:** The correct use of an ICD-10-CM code listed in the "ICD-10 Codes that Support Medical Necessity" section does not guarantee coverage of a service. The service must be reasonable and necessary in the specific case and must meet the criteria specified in this LCD.

ICD-10 codes must be coded to the highest level of specificity. Consult the 'Official ICD-10-CM Guidelines for Coding and Reporting' in the current ICD-10-CM book for correct coding guidelines. This LCD does not take precedence over the Correct Coding Initiative (CCI).

**CPT Codes 81370-81383**

**Group 1 Codes:**

<table>
<thead>
<tr>
<th>ICD-10 Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>R56.00 - R56.819</strong></td>
<td>Unspecified complication of bone marrow transplant - Unspecified complication of lung transplant</td>
</tr>
<tr>
<td><strong>T86.30 - T86.39</strong></td>
<td>Bone graft rejection - Unspecified complication of bone graft</td>
</tr>
<tr>
<td><strong>T86.850 - T86.99</strong></td>
<td>Intestine transplant rejection - Other complications of unspecified transplanted organ and tissue</td>
</tr>
<tr>
<td><strong>Z48.21 - Z48.298</strong></td>
<td>Encounter for aftercare following heart transplant - Encounter for aftercare following other organ transplant</td>
</tr>
<tr>
<td><strong>Z94.0 - Z94.9</strong></td>
<td>Kidney transplant status - Transplanted organ and tissue status, unspecified</td>
</tr>
<tr>
<td><strong>Z95.3 - Z95.4</strong></td>
<td>Presence of xenogenic heart valve - Presence of other heart-valve replacement</td>
</tr>
</tbody>
</table>

**Group 2 Paragraph: CPT Code 81374 for HLA-B*27 Testing**

**Group 2 Codes:**

<table>
<thead>
<tr>
<th>ICD-10 Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>M08.1</strong></td>
<td>Juvenile ankylosing spondylitis</td>
</tr>
<tr>
<td><strong>M45.0 - M45.9</strong></td>
<td>Ankylosing spondylitis of multiple sites in spine - Ankylosing spondylitis of unspecified sites in spine</td>
</tr>
<tr>
<td><strong>M48.8X1 - M48.8X9</strong></td>
<td>Other specified spondylopathies, occipito-atlanto-axial region - Other specified spondylopathies, site unspecified</td>
</tr>
</tbody>
</table>

**Group 3 Paragraph: CPT code 81381 for HLA-B*1502 Testing**

**Group 3 Codes:**

<table>
<thead>
<tr>
<th>ICD-10 Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>R56.00 - R56.9</strong></td>
<td>Simple febrile convulsions - Unspecified convulsions</td>
</tr>
<tr>
<td><strong>Z79.3</strong></td>
<td>Long term (current) use of hormonal contraceptives</td>
</tr>
<tr>
<td><strong>Z79.891</strong></td>
<td>Long term (current) use of opiate analgesics</td>
</tr>
<tr>
<td><strong>Z79.899</strong></td>
<td>Other long term (current) drug therapy</td>
</tr>
</tbody>
</table>

Printed on 11/11/2015. Page 5 of 9
<table>
<thead>
<tr>
<th>ICD-10 Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>B20</td>
<td>Human immunodeficiency virus [HIV] disease</td>
</tr>
<tr>
<td>Z21</td>
<td>Asymptomatic human immunodeficiency virus [HIV] infection status</td>
</tr>
</tbody>
</table>

**Group 4 Paragraph: CPT code: 81381 for HLA-B*5701 Testing**

**Group 4 Codes:**

<table>
<thead>
<tr>
<th>ICD-10 Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>K90.0</td>
<td>Celiac disease</td>
</tr>
</tbody>
</table>

**Group 5 Paragraph: CPT codes 81376, 81377, 81382, and 81383**

**Group 5 Codes:**

<table>
<thead>
<tr>
<th>ICD-10 Codes</th>
<th>Description</th>
</tr>
</thead>
</table>

ICD-10 Codes that DO NOT Support Medical Necessity N/A
ICD-10 Additional Information

**General Information**

Associated Information

**Documentation Requirements**

1. All 'Indications' must be clearly documented in the patient’s medical record and made available to Medicare upon request.

2. The laboratory or billing provider must have on file the physician requisition which sets forth the diagnosis or condition (ICD-9-CM code) that warrants the test(s).

3. When the documentation does not meet the criteria for the services rendered, or the documentation does not establish the medical necessity for the services, such services will be denied as not reasonable and necessary under Section 1862(a)(1) of the Social Security Act.

4. Documentation must support CMS 'signature requirements' as described in the Medicare Program Integrity Manual (Pub. 100-08), Chapter 3.

**Utilization Guidelines**

Screening services, such as pre-symptomatic genetic tests and services used to detect an undiagnosed disease or disease predisposition are not a Medicare benefit and not covered.

**Sources of Information and Basis for Decision**

- ASHI Quarterly - Fourth Quarter 2010. HLA Alleles and Drug Hypersensitivity Reactions.
• Consultations with the representatives to the Carrier Advisory Committee and other Medicare Contractors.
• Lab Tests Online.
• Nanosphere. Nanosphere Receives FDA Clearance to Market Test for Detection of CYP2C19 Mutations Affecting Drug Metabolism.
• Other Medicare Contractor’s Local Coverage Determinations.
• Quest Diagnostics. HLA Test Menu.
• UCLA Immunogenetics Center.
• U.S. Food and Drug Administration. Information on Carbamazapine (marketed as Carbatrol, Equetro, Tegretol, and generics).

Revision History Information

Please note: Most Revision History entries effective on or before 01/24/2013 display with a Revision History Number of "R1" at the bottom of this table. However, there may be LCDs where these entries will display as a separate and distinct row.
<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Revision History Number</th>
<th>Revision History Explanation</th>
<th>Reason(s) for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/01/2015</td>
<td>R2</td>
<td>Corrected typographical error.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>NOTE:</strong> The link,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><a href="http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm121646.htm">http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm121646.htm</a>,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>is no longer active. Therefore, this was removed from the Sources of Information and Basis for Decision section of this LCD.</td>
<td></td>
</tr>
</tbody>
</table>